Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SCD | O00767 | 1/20 | 0.44 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | MYT1 | Q01538 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12208896 | 0.81 | P2RX7 (0.48) | P2RX7SCDSCD5CDK1MYT1 | |
| SCHEMBL25937516 | 0.80 | SIGMAR1 (0.47) | P2RX7SCDSCD5ALDH1A1CDK1 | |
| SCHEMBL25937008 | 0.80 | WNT3 (0.40) | P2RX7GPR119SCDSCD5CDK1 | |
| SCHEMBL25938042 | 0.80 | WNT3 (0.40) | P2RX7GPR119SCDSCD5CDK1 | |
| SCHEMBL12332203 | 0.79 | SCD (0.49) | P2RX7SCDSCD5CDK1MYT1 | |
| SCHEMBL4400866 | 0.77 | NR1H2 (0.43) | POLBMAPK1NR1H2MAPTESR2 | |
| SCHEMBL31377191 | 0.77 | P2RX7 (0.36) | P2RX7SCDSCD5ALDH1A1CDK1 | |
| SCHEMBL21410419 | 0.77 | SCD (0.53) | P2RX7SCDSCD5CDK1MYT1 | |
| SCHEMBL19722677 | 0.75 | SCD (0.49) | P2RX7SCDSCD5CDK1MYT1 | |
| SCHEMBL31622168 | 0.75 | SCD (0.49) | P2RX7SCDSCD5CDK1MYT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024411-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12624041-B2 | Heterocyclic compound and use thereof | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2026-05-12 | — | — | US | disclosed |
| WO-2025101780-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | OCTANT, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| US-20250066344-A1 | BENZOTHIAZOLE, BENZOISOXAZOLE, AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2025-02-27 | — | — | US | disclosed |
| EP-4448500-A1 | BENZOTHIAZOLE, BENZOISOXAZOLE AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240317755-A1 | HETEROCYCLIC COMPOUND, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2024-09-26 | — | — | US | disclosed |
| CN-118401502-A | Benzothiazole, benzisoxazole and benzodioxole analogs as RXFP1 receptor agonists | 百时美施贵宝公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-118103369-A | Pyridolactam derivatives, preparation method and application thereof | 浙江海正药业股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-114907408-B | Heterocyclic compound, intermediate thereof, preparation method and application thereof | 武汉朗来科技发展有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-111936468-B | Compounds with anticancer activity | 协和麒麟株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-7795262-B2 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | NEUROGEN CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100009993-A1 | Diketo Fused Azolopiperidines and Azolopiperazines as Anti-HIV Agents | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-14 | — | — | US | disclosed |
| WO-2009158394-A1 | DIKETO AZOLOPIPERIDINES AND AZOLOPIPERAZINES AS ANTI-HIV AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-30 | — | — | WO | disclosed |
| US-20070232591-A1 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | NEUROGEN CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070232591-A1 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | NEUROGEN CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070232591-A1 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | NEUROGEN CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7144887-B2 | Substituted 1,2,3-triazolo[1,5-a]quinazolines for enhancing cognition | MERCK SHARP & DOHME LTD. (GB) | 2006-12-05 | — | — | US | disclosed |
| EP-1286967-B1 | CYCLOHEXANE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME (GB) | 2006-09-27 | — | — | EP | disclosed |
| US-7105507-B2 | Cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236250-A1 | Cyclohexane derivatives and their use as therapeutic agents | CNR2, CNR1, HTR1A | P2RX7 32/4885POLB 2365/4885GPR119 923/4885 |
| US-20070232591-A1 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | HRH3, HRH4, HRH1 | P2RX7 257/4885POLB 3403/4885GPR119 226/4885 |
| US-12624041-B2 | Heterocyclic compound and use thereof | TRPC1, TRPC5, TRPC3 | P2RX7 1449/4885POLB 3847/4885GPR119 592/4885 |
| US-20100009993-A1 | Diketo Fused Azolopiperidines and Azolopiperazines as Anti-HIV Agents | DHFR, DHPS, DCK | P2RX7 3549/4885POLB 1498/4885GPR119 1545/4885 |
| US-20250066344-A1 | BENZOTHIAZOLE, BENZOISOXAZOLE, AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS | RXFP1, RXFP2, RXFP3 | P2RX7 309/4885POLB 4768/4885GPR119 85/4885 |
| US-20240317755-A1 | HETEROCYCLIC COMPOUND, AND INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | CYP4A11, CYP4F11, CYP51A1 | P2RX7 2855/4885POLB 3759/4885GPR119 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.